spacer
spacer

PDBsum entry 5a85

Go to PDB code: 
protein ligands links
Hydrolase PDB id
5a85

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
126 a.a.
Ligands
EDO
78J
Waters ×232
PDB id:
5a85
Name: Hydrolase
Title: N-terminal bromodomain of human brd4 with 8-(3r,4r)-3- (cyclohexylmethoxy)piperidin-4-ylamino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one
Structure: Bromodomain-containing protein 4. Chain: a. Fragment: n-terminal bromodomain, residues 44-168. Synonym: protein hunk1, brd4. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
1.72Å     R-factor:   0.188     R-free:   0.236
Authors: C.Chung,P.Bamborough,E.Demont
Key ref: P.Bamborough et al. (2015). Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. J Med Chem, 58, 6151-6178. PubMed id: 26230603 DOI: 10.1021/acs.jmedchem.5b00773
Date:
11-Jul-15     Release date:   12-Aug-15    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
O60885  (BRD4_HUMAN) -  Bromodomain-containing protein 4 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1362 a.a.
126 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: E.C.?
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

 

 
DOI no: 10.1021/acs.jmedchem.5b00773 J Med Chem 58:6151-6178 (2015)
PubMed id: 26230603  
 
 
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.
P.Bamborough, C.W.Chung, R.C.Furze, P.Grandi, A.M.Michon, R.J.Sheppard, H.Barnett, H.Diallo, D.P.Dixon, C.Douault, E.J.Jones, B.Karamshi, D.J.Mitchell, R.K.Prinjha, C.Rau, R.J.Watson, T.Werner, E.H.Demont.
 
  ABSTRACT  
 
ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphthyridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.
 

 

spacer

spacer